Swan Capital’s Transmedics TMDX Stock Holding History

Swan Capital’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8	Closed	-$795	–	618
2026 Q1	$795	Hold	8	–	–	﹤0.01%	466
2025 Q4	$973	Buy	+8	New	+$1K	﹤0.01%	406

Other funds holding TMDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Swan Capital's TMDX Position: Q2 2026 in Review

Swan Capital sold out of Transmedics (TMDX) in Q2 2026, closing a stake of 8 shares — an estimated $795 sold.

Swan Capital first reported a position in TMDX in Q4 2025 and held it in 2 quarters. The position peaked at $973 in Q4 2025. 375 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

Swan Capital reported no remaining Transmedics position as of Q2 2026 after selling out during the quarter.
Swan Capital sold 8 Transmedics shares in Q2 2026, an estimated $795.
Swan Capital first reported a position in Transmedics in Q4 2025 and held it in 2 quarters.
Swan Capital's Transmedics position peaked at $973 in Q4 2025.
375 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.